Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John C Kraft

Showing results (1-10 of 32) with videos related to

Pageof 4
Sort By:
Current Opinion in Anaesthesiology|May 5, 2010
Pharmacogenetics in obstetric anesthesiaRuth Landau, John C Kraft
Biochemistry|February 12, 2014
Interactions of indocyanine green and lipid in enhancing near-infrared fluorescence properties: the basis for near-infrared imaging in vivoJohn C Kraft, Rodney J Y Ho
Journal of Drug Targeting|February 2, 2018
Indocyanine green nanoparticles undergo selective lymphatic uptake, distribution and retention and enable detailed mapping of lymph vessels, nodes and abnormalitiesJohn C Kraft, Piper M Treuting, Rodney J Y Ho
European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Fur Pharmazeutische Verfahrenstechnik E.V|April 22, 2018
Recent developments of nanotherapeutics for targeted and long-acting, combination HIV chemotherapyYu Gao, John C Kraft, Danni Yu, et al.
Journal of Pharmaceutical Sciences|December 17, 2013
Emerging research and clinical development trends of liposome and lipid nanoparticle drug delivery systemsJohn C Kraft, Jennifer P Freeling, Ziyao Wang, et al.
Nanomedicine (London, England)|February 20, 2016
Nanodrug formulations to enhance HIV drug exposure in lymphoid tissues and cells: clinical significance and potential impact on treatment and eradication of HIV/AIDSJingwei Shao, John C Kraft, Bowen Li, et al.
Drug Delivery and Translational Research|August 29, 2015
Systems Approach to targeted and long-acting HIV/AIDS therapyRodney J Y Ho, Jesse Yu, Bowen Li, et al.
AIDS (London, England)|August 14, 2018
Extended cell and plasma drug levels after one dose of a three-in-one nanosuspension containing lopinavir, efavirenz, and tenofovir in nonhuman primatesJosefin Koehn, Jennifer F Iwamoto, John C Kraft, et al.
Journal of Drug Targeting|December 30, 2017
Translation of combination nanodrugs into nanomedicines: lessons learned and future outlookQingxin Mu, Jesse Yu, Lisa A McConnachie, et al.
Journal of Pharmaceutical Sciences|August 20, 2018
Three HIV Drugs, Atazanavir, Ritonavir, and Tenofovir, Coformulated in Drug-Combination Nanoparticles Exhibit Long-Acting and Lymphocyte-Targeting Properties in Nonhuman PrimatesSimone Perazzolo, Laura M Shireman, Josefin Koehn, et al.
Pageof 4

Showing results (1-10 of 32) with videos related to

Sort By:
Pageof 4
Current Opinion in Anaesthesiology|May 5, 2010
Pharmacogenetics in obstetric anesthesiaRuth Landau, John C Kraft
Biochemistry|February 12, 2014
Interactions of indocyanine green and lipid in enhancing near-infrared fluorescence properties: the basis for near-infrared imaging in vivoJohn C Kraft, Rodney J Y Ho
Journal of Drug Targeting|February 2, 2018
Indocyanine green nanoparticles undergo selective lymphatic uptake, distribution and retention and enable detailed mapping of lymph vessels, nodes and abnormalitiesJohn C Kraft, Piper M Treuting, Rodney J Y Ho
European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Fur Pharmazeutische Verfahrenstechnik E.V|April 22, 2018
Recent developments of nanotherapeutics for targeted and long-acting, combination HIV chemotherapyYu Gao, John C Kraft, Danni Yu, et al.
Journal of Pharmaceutical Sciences|December 17, 2013
Emerging research and clinical development trends of liposome and lipid nanoparticle drug delivery systemsJohn C Kraft, Jennifer P Freeling, Ziyao Wang, et al.
Nanomedicine (London, England)|February 20, 2016
Nanodrug formulations to enhance HIV drug exposure in lymphoid tissues and cells: clinical significance and potential impact on treatment and eradication of HIV/AIDSJingwei Shao, John C Kraft, Bowen Li, et al.
Drug Delivery and Translational Research|August 29, 2015
Systems Approach to targeted and long-acting HIV/AIDS therapyRodney J Y Ho, Jesse Yu, Bowen Li, et al.
AIDS (London, England)|August 14, 2018
Extended cell and plasma drug levels after one dose of a three-in-one nanosuspension containing lopinavir, efavirenz, and tenofovir in nonhuman primatesJosefin Koehn, Jennifer F Iwamoto, John C Kraft, et al.
Journal of Drug Targeting|December 30, 2017
Translation of combination nanodrugs into nanomedicines: lessons learned and future outlookQingxin Mu, Jesse Yu, Lisa A McConnachie, et al.
Journal of Pharmaceutical Sciences|August 20, 2018
Three HIV Drugs, Atazanavir, Ritonavir, and Tenofovir, Coformulated in Drug-Combination Nanoparticles Exhibit Long-Acting and Lymphocyte-Targeting Properties in Nonhuman PrimatesSimone Perazzolo, Laura M Shireman, Josefin Koehn, et al.
Pageof 4